Tocagen Inc (NASDAQ:TOCA) has been given an average rating of “Buy” by the eleven analysts that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $16.00.
Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Friday. Chardan Capital reissued a “buy” rating and set a $10.00 target price on shares of Tocagen in a research report on Wednesday, May 22nd. Leerink Swann set a $5.00 target price on shares of Tocagen and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. ValuEngine raised shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating on shares of Tocagen in a research report on Friday, August 9th.
Shares of NASDAQ:TOCA traded up $0.16 during midday trading on Friday, hitting $4.52. 263,000 shares of the company’s stock were exchanged, compared to its average volume of 174,154. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 5.05. The stock has a 50 day moving average price of $5.51 and a 200-day moving average price of $8.18. The company has a market cap of $102.76 million, a PE ratio of -1.85 and a beta of 3.90. Tocagen has a 12 month low of $4.12 and a 12 month high of $15.80.
In other news, Director Faheem Hasnain acquired 43,000 shares of Tocagen stock in a transaction on Thursday, May 30th. The stock was acquired at an average cost of $4.66 per share, with a total value of $200,380.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired a total of 53,000 shares of company stock valued at $244,880 over the last ninety days. 10.90% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Tocagen by 0.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,068,135 shares of the company’s stock worth $7,135,000 after acquiring an additional 6,260 shares during the last quarter. A.R.T. Advisors LLC bought a new stake in Tocagen in the 2nd quarter worth $114,000. BlackRock Inc. grew its holdings in Tocagen by 0.7% in the 2nd quarter. BlackRock Inc. now owns 1,672,165 shares of the company’s stock worth $11,171,000 after acquiring an additional 11,152 shares during the last quarter. Parametric Portfolio Associates LLC bought a new stake in Tocagen in the 2nd quarter worth $75,000. Finally, IPG Investment Advisors LLC bought a new stake in Tocagen in the 2nd quarter worth $134,000. 35.06% of the stock is owned by institutional investors and hedge funds.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.